In the wake of several Risperdal trials going to verdict this year, parties on both sides of the litigation are contesting the amounts juries awarded.

In recent post-trial filings in two Risperdal cases, Janssen Pharmaceuticals has argued the verdicts, both of which were over $1 million, should be reduced. The plaintiff in a third case—the most recent to come to a verdict—is also contesting the $500,000 award in that case, arguing the court erred in foreclosing any future damages award.